Guihua Jia

Guihua Jia

Auto-generated profile, based on publicly available information

Guihua Jia

School of Pharmaceutical Sciences, Jilin University Changchun China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
DWDan-Dan Wang
Dan-Dan Wang
XQXing-Kai Qian
Xing-Kai Qian
HLHongxin Li
Hongxin Li
GJGui-Hua Jia
Gui-Hua Jia
QJQiang Jin
Qiang Jin
LYLing Yang
Ling Yang

22 April 2025 in PeerJ Computer Science
Verified
Journal Article
Open access
PDF file
RLRongpei Li
Rongpei Li
YZYufang Zhang
Yufang Zhang
HSHeqi Sun
Heqi Sun
SLShenggeng Lin
Shenggeng Lin
GJGuihua Jia
Guihua Jia
DWDong-Qing Wei
Dong-Qing Wei
Background: Drug-drug interactions (DDIs) account for 17–23% of adverse drug reactions leading to hospitalization, with over 74,000 DDI-related events reported in the FDA Adverse Event Reporting System (FAERS) during 2023. While recent computational methods focus on improving prediction accuracy, they suffer from high false-positive rates (>45%) and often function as black-box models without biological interpretability. Methods: We propose Dual-stage attention and Bayesian calibration with active learning Drug-Drug Interaction (DABI-DDI), a novel framework integrating: (1) A dual-stage attention mechanism with LSTM networks for capturing temporal dependencies in drug interactions, (2) a Bayesian calibration approach with beta-binomial modeling for refining interaction signals and reducing false positives, (3) an active learning strategy for efficient sample selection, and (4) a network pharmacology component linking drug interactions to underlying biological mechanisms. The model was validated using data from FAERS, DrugBank, and STRING databases, with comprehensive evaluation on both computational performance and biological interpretability. Results: DABI-DDI achieved superior performance (AUC = 0.947, PR_AUC = 0.944). Bayesian calibration improved adverse event detection accuracy (94% vs. 54% AUC), while network pharmacology revealed key molecular mechanisms through enzyme-transporter interactions. Ablation studies demonstrated each component’s significance, with active learning maintaining performance while reducing training data requirements. Conclusion: We present DABI-DDI, an integrated feature extraction framework that successfully addresses key challenges in DDIs prediction through three major innovations: Temporal pattern recognition, reducing false positives, and biological interpretability. Most importantly, the framework demonstrates strong clinical applicability by efficiently identifying high-risk drug combinations while providing mechanistic insights through enzyme-transporter pathway analysis. This approach bridges the gap between computational prediction and clinical understanding, offering a promising tool for safer drug combination therapy.

18 December 2025 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
GJGuihua Jia
Guihua Jia
JLJiayi Li
Jiayi Li
AKAbbas Khan
Abbas Khan
AKAman Chandra Kaushik
Aman Chandra Kaushik
DWDiyi Wu
Diyi Wu
DWDong-Qing Wei
Dong-Qing Wei

6 December 2013
Verified
Book Chapter
Closed access
PDF file
LRLihong Ruan
Lihong Ruan
ZFZhenghui Fang
Zhenghui Fang
JTJingxia Tian
Jingxia Tian
YDYan Dou
Yan Dou
WZWenyu Zhong
Wenyu Zhong
HWHongqiao Wu
Hongqiao Wu